Superior cardiovascular protection with GLP-1 RAs over SGLT2 inhibitors in DM and HFpEF: A propensity score matching study.

ABSTRACT:

Background

Heart failure with preserved ejection fraction (HFpEF) and diabetes mellitus (DM) are interrelated conditions associated with high morbidity and mortality. This study compared the cardiovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus sodium-glucose cotransporter-2 (SGLT2) inhibitors in this population.

Methods

This retrospective cohort study used data from the TriNetX database. It included 2,177 matched pairs of patients with HFpEF and DM treated with either GLP-1 RAs or SGLT2 inhibitors. Outcomes assessed over three years were a composite of all-cause mortality and progression to systolic heart failure, acute myocardial infarction, or stroke.

Results

GLP-1 RAs significantly reduced the risk of composite outcomes

SUBMITTER: Li AC 

PROVIDER: S-EPMC12200838 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature